Some people may know of this drug as OT-58, but it's proper name is TVT-058.
In November 2020, Retrophin acquired Orphan Technologies, thus also acquiring OT-58 and their Natural History Study. Shortly after, Retrophin rebranded as Travere.
Travere Therapeutics is in the process of developing an enzyme replacement therapy for patients with CBS Deficiency Homocystinuria.
For the most up to date news on their enzyme replacement, please visit their website: Click here